These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 18390581

  • 1. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis.
    McGonagle D, Tan AL, Madden J, Taylor L, Emery P.
    Rheumatology (Oxford); 2008 Jun; 47(6):865-7. PubMed ID: 18390581
    [Abstract] [Full Text] [Related]

  • 2. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN, Masding A, Somerville M, Gaffney K, Scott DG.
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [Abstract] [Full Text] [Related]

  • 3. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 4. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.
    Scand J Rheumatol; 2009 Dec; 38(5):323-7. PubMed ID: 19585384
    [Abstract] [Full Text] [Related]

  • 5. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S.
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [Abstract] [Full Text] [Related]

  • 6. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.
    Thurlings RM, Vos K, Gerlag DM, Tak PP.
    Arthritis Rheum; 2008 Dec; 58(12):3657-64. PubMed ID: 19035505
    [Abstract] [Full Text] [Related]

  • 7. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 8. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [Abstract] [Full Text] [Related]

  • 9. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N, Gossec L, Dieudé P, Meyer O, Dougados M, Kahan A, Allanore Y.
    J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F.
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [Abstract] [Full Text] [Related]

  • 11. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A.
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [Abstract] [Full Text] [Related]

  • 13. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?
    Pocock JM, Vasconcelos JC, Ostör AJ.
    Rheumatology (Oxford); 2008 Jul; 47(7):1073-6. PubMed ID: 18503089
    [Abstract] [Full Text] [Related]

  • 14. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, British Society for Rheumatology Biologics Register.
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM.
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [Abstract] [Full Text] [Related]

  • 17. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers.
    Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM.
    J Clin Rheumatol; 2010 Jan; 16(1):15-8. PubMed ID: 20051749
    [Abstract] [Full Text] [Related]

  • 18. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M.
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [Abstract] [Full Text] [Related]

  • 19. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [Abstract] [Full Text] [Related]

  • 20. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
    Buch MH, Bingham SJ, Bryer D, Emery P.
    Rheumatology (Oxford); 2007 Jul; 46(7):1153-6. PubMed ID: 17478470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.